Russia Registers First Domestic Meningococcal Vaccine

Russia registered its first domestically produced tetravalent vaccine against meningococcal infection, according to TASS in Petrovax Pharm.

Consensus

The Russian Ministry of Health registered the first domestic four-valent conjugated vaccine against meningococcal infection, 'Mentetra.'
The vaccine protects against serogroups A, C, W and Y of meningococcus.
The registration was announced by 'Petrovax Farm' on September 28.
Investments in the full-cycle production of the vaccine exceeded 3 billion rubles.
The vaccine is intended for use in the National Calendar of Preventive Vaccinations, with inclusion planned for 2027.
Meningococcal infection is a severe bacterial disease with high lethality, particularly among children, adolescents, elderly, and immunocompromised individuals.
The disease spreads via airborne droplets and can lead to severe complications or death within 24 hours.
The vaccine's registration enables broader national immunization and reduces reliance on imported products.

Veronika Skvortsova, head of FMBA Russia, announced in June the upcoming market launch of a domestic pentavalent meningococcal vaccine 'Mengovaks B' in 2026, which is unique globally and targets serogroup B. — vedomosti
In 2025, over one-third of meningococcal infections in Russia were among migrants from neighboring countries, with a 2.7-fold increase in incidence compared to 2024. — vedomosti
As of the time of reporting, the vaccine's data had not yet appeared in the state drug registry. — kommersant
36% of infected individuals in 2025 were labor migrants from neighboring countries lacking immunity to serogroup A strains circulating in Russia. — kommersant
Meningococcal infection is the leading cause of death among children from infectious diseases. — tg_tass_agency
The vaccine underwent Phase III clinical trials in 18 medical centers in 2025. — vesti
The Ministry of Health originally planned to expand the vaccination calendar by the end of 2025, but the timeline was delayed to 2027. — kommersant